2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 344

Factors Associated with the Disappearance of Calcifications Following Ultrasound Guided Percutaneous Lavage of Rotator Cuff Calcific Tendinopathy: A Post Hoc Analysis of a Randomized Controlled Trial
Abstract Number: 345

Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey
Abstract Number: 346

Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Abstract Number: 347

Patterns and Clinico-Radiological Correlates of Symptomatic Atlantoaxial Joint Involvement in Patients with Calcium Pyrophosphate Deposition Disease
Abstract Number: 348

Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry
Abstract Number: 349

Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study
Abstract Number: 350

Rapid Reduction in Uric Acid Is Associated with Recurrent Cardiovascular Events
Abstract Number: 351

Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnameses: Results of a Prospective Study in Ho Chi Minh City
Abstract Number: 352

Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis
Abstract Number: 353

Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study
Abstract Number: 354

Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Abstract Number: 355

Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol
Abstract Number: 356

Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Abstract Number: 357

Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification
Abstract Number: 358

Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.